In recent years, a growing understanding of myotonic dystrophy type 1 (DM1)—an often fatal, devastating, rare neuromuscular disorder that causes muscle weakness and other life-limiting ...

People with myotonic dystrophy type 1 (DM1), the most common adult-onset form ... Clarence and Irene H. Fulbright Professor ...

(DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic dystrophy type 1 is a genetic disease that ...

The analysis indicates that in 2023, the US had approximately 43,255 diagnosed cases of Myotonic Dystrophy Type 1 and 10,815 cases of Myotonic Dystrophy Type 2. This data highlights a significant ...

Keep abreast with the latest news related to Myotonic Dystrophy there are 6 news items on Myotonic Dystrophy that covers updates, breakthroughs and in-depth reports. We provide you with a free ...

Dyne CEO Joshua Brumm said that this year the Phase 1/2 studies in myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy will each optimize the dose and dose regimen to test in a cohort ...

H.C. Wainwright keeps a Buy rating on Dyne Therapeutics (DYN) with a $55 price target after the company announced the 6.8 mg/Kg eight week ...

It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph.

Patients with myotonic dystrophy have smaller hearts, and lower systolic and diastolic blood pressures and pulse rates. They have impaired autonomic reflexes, measured by orthostatic, Valsalva ...